Journal
NATURE CHEMICAL BIOLOGY
Volume 11, Issue 10, Pages 779-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.1895
Keywords
-
Categories
Funding
- Fundacao para a Ciencia e Tecnologia (FCT-MEC) [UID/Multi/04378/2013, EXCL/QEQ-COM/0394/2012, PTDC/BIA-PRO/118377/2010, SFRH/BPD/84581/2012, DAAD-441.00]
- Deutsche Forschungsgemeinschaft Grant [Le1171/8-1]
- European Community [283570]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/84581/2012, EXCL/QEQ-COM/0394/2012, PTDC/BIA-PRO/118377/2010] Funding Source: FCT
Ask authors/readers for more resources
Aldehyde oxidase (AOX) is a xanthine oxidase (XO)-related enzyme with emerging importance due to its role in the metabolism of drugs and xenobiotics. We report the first crystal structures of human AOX1, substrate free (2.6-angstrom resolution) and in complex with the substrate phthalazine and the inhibitor thioridazine (2.7-angstrom resolution). Analysis of the protein active site combined with steady-state kinetic studies highlight the unique features, including binding and substrate orientation at the active site, that characterize human AOX1 as an important drug-metabolizing enzyme. Structural analysis of the complex with the noncompetitive inhibitor thioridazine revealed a new, unexpected and fully occupied inhibitor-binding site that is structurally conserved among mammalian AOXs and XO. The new structural insights into the catalytic and inhibition mechanisms of human AOX that we now report will be of great value for the rational analysis of clinical drug interactions involving inhibition of AOX1 and for the prediction and design of AOX-stable putative drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available